National Jewish Health

4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

Retrieved on: 
Thursday, May 11, 2023
Pediatrics, Gene, National Jewish Health, VG, Cohort, MSCS, Cystic fibrosis, RNA, CFTR, Science, Patient, Annual general meeting, Cell, Safety, Society, FEV1, Conference, Pharmaceutical industry, Medicine

The oral presentation will be given by Jennifer L. Taylor-Cousar, M.D., MSCS, Professor, Departments of Medicine and Pediatrics, and Co-Director, Adult Cystic Fibrosis Program, Director, Cystic Fibrosis Foundation Therapeutics Development Center, National Jewish Health.

Key Points: 
  • The oral presentation will be given by Jennifer L. Taylor-Cousar, M.D., MSCS, Professor, Departments of Medicine and Pediatrics, and Co-Director, Adult Cystic Fibrosis Program, Director, Cystic Fibrosis Foundation Therapeutics Development Center, National Jewish Health.
  • In situ hybridization biomarker data, demonstrating transgene RNA expression from lung samples from Cohort 1 patients, was previously presented by Dr. Taylor-Cousar at the North American Cystic Fibrosis Conference (NACFC), November 3, 2022.
  • Additional clinical and biomarker data for Cohort 1 patients (n=3; 9-12 months follow-up) are expected to be presented at the European Cystic Fibrosis Conference in June 2023.
  • Clinical data will focus on safety, tolerability, pulmonary function testing (e.g., percent predicted FEV1) and respiratory-related quality of life assessments.

Abata Therapeutics Announces the Appointment of Leonard Dragone, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Thursday, April 20, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, JDRF, Angeles volunteer association, University of Colorado School of Medicine, Drug development, University, National Jewish Health, T1D, Pediatrics, University of California, San Francisco, INVU (album), Rheumatology, CMO, Multiple sclerosis, Biomarker, Bangladesh Technical Education Board, TCR, Merck & Co., Foundation for the National Institutes of Health, MS, Science, Regulatory T cell, Third Rock Ventures, Patient, UCSF, Autoimmune disease, Lightspeed Venture Partners, Biology, Knowledge, Therapy, IND, Autoimmunity, Inflammation, Pharmaceutical industry, Nursing, Genentech

Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases, today announced the appointment of Leonard “Lenny” Dragone, M.D., Ph.D., as its new chief medical officer.

Key Points: 
  • Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases, today announced the appointment of Leonard “Lenny” Dragone, M.D., Ph.D., as its new chief medical officer.
  • Dr. Dragone brings to Abata extensive experience in preclinical and early clinical development and autoimmune medicine.
  • I’m thrilled he’ll be joining us to advance this work.”
    Dr. Dragone most recently served as chief medical officer at Sonoma Biotherapeutics.
  • Abata Therapeutics is focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases.

Zura Bio Announces Appointment of Chief Scientific Officer

Retrieved on: 
Friday, April 14, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, BS, National Jewish Health, Messiah University, Research fellow, University School, MedImmune, Doctor of Philosophy, Boehringer Ingelheim, Inflammation, Acquisition, Patient, Division, West Virginia University School of Medicine, Immune tolerance, Zeneca, Biology, Pharmaceutical industry, Allergy, Immunology, Medicine

Zura Bio Limited (Nasdaq: “ZURA”) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the appointment of Michael D. Howell, Ph.D., to the role of Chief Scientific Officer and Head of Translational Science.

Key Points: 
  • Zura Bio Limited (Nasdaq: “ZURA”) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the appointment of Michael D. Howell, Ph.D., to the role of Chief Scientific Officer and Head of Translational Science.
  • Dr. Howell brings more than two decades of experience leading discovery, translational research, and early clinical programs and will lead the scientific strategy and translational science efforts at Zura Bio.
  • “I am thrilled to have Michael Howell join our team as our Chief Scientific Officer and Head of Translational Science,” said Someit Sidhu, M.D., CEO of Zura Bio.
  • He formerly served as the Chief Scientific Officer of DermTech, Inc.

Cerner Enviza Collaborates with FDA to Develop Innovative AI Tools for Drug Safety and Real-World Evidence Studies

Retrieved on: 
Monday, April 10, 2023
Sentinel, Natural language processing, National Jewish Health, Health, Cerner Enviza, Oracle Cloud, Orange County, NLP, Pharmacoepidemiology, Children's Hospital of Orange County, Patient, EHR, Physician, Machine learning, Mass, Harvard Pilgrim Health Care, Mass General Brigham, Spark NLP, Artificial intelligence, Knowledge, Multi, Sentinel Initiative, Hospital, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Mental health, Conference, Health information management, Food, Pharmaceutical industry, Management, Nursing, Oracle

AUSTIN, Texas, April 10, 2023 /PRNewswire/ -- Cerner Enviza, an Oracle company, along with John Snow Labs, are now helping support the U.S. Food and Drug Administration's drug safety Sentinel Initiative. By developing artificial intelligence (AI) tools aimed at extracting critical information from clinical notes within electronic health records (EHR), Oracle and John Snow will aid the FDA in better understanding the effects of medicines on large populations. Looking at the asthma drug, montelukast, and its possibility of mental health side effects, this two-year project will demonstrate how the use of machine learning and natural language processing (NLP) technology with unstructured data may help fill gaps in knowledge.

Key Points: 
  • AUSTIN, Texas, April 10, 2023 /PRNewswire/ -- Cerner Enviza , an Oracle company, along with John Snow Labs , are now helping support the U.S. Food and Drug Administration's drug safety Sentinel Initiative.
  • Cerner Enviza leverages decades of life sciences expertise spanning commercial, real world, clinical and regulatory research.
  • John Snow Labs is known for its AI and NLP in healthcare and is the developer of the Spark NLP library.
  • Together, Cerner Enviza and John Snow Labs have all the right expertise, data, and technology to make it happen."

PF Warriors Announces Teresa Barnes and Dolly Kervitsky to Join Executive Leadership Team

Retrieved on: 
Tuesday, February 28, 2023
Human, Quality of life, Executive Committee, American Thoracic Society, Rare, Capitol Hill, National Jewish Health, S-1 Executive Committee, CPF, Medical Affairs Bureau, Trustee, Organization, Coalition, Research, Patient, Fibrosis, PFF, Hope, Growth, Pulmonary fibrosis, Empathy, Shelly, NIH, Face, Idiopathic pulmonary fibrosis, Barnes, IPF, PF, Caregiver, ATS, Nursing care plan, Nursing, Management, Pharmaceutical industry

DALLAS, Feb. 28, 2023 /PRNewswire/ -- PF Warriors, the largest pulmonary fibrosis (PF) patient support group dedicated to patients helping patients, announced the appointments of Teresa Barnes and Dolly Kervitsky to executive leadership positions.

Key Points: 
  • DALLAS, Feb. 28, 2023 /PRNewswire/ -- PF Warriors, the largest pulmonary fibrosis (PF) patient support group dedicated to patients helping patients, announced the appointments of Teresa Barnes and Dolly Kervitsky to executive leadership positions.
  • Teresa Barnes and Dolly Kervitsky selected to executive leadership positions at PF Warriors.
  • "Teresa and Dolly have been entrenched in the PF community for many years, fighting for patients and their families.
  • "PF Warriors touches so many patients and caregivers globally because of its empathy and ability to give families hope," noted Kervitsky.

Mount Sinai Researchers Awarded $12 Million NIH Grant to Create a Center to Unravel Novel Causes of Food Allergy & Atopic Dermatitis That Uses a Systems Biology Approach

Retrieved on: 
Thursday, January 26, 2023
University of North Carolina at Pembroke, University, Sunbeam, Atopic dermatitis, MPH, Johns Hopkins, Diagnosis, Bangladesh Technical Education Board, Skin, Infection, National Institute of Allergy and Infectious Diseases, Systems biology, Anaphylaxis, Periodic breathing, Master of Philosophy, Sinai, Risk, Dermatitis, Food allergy, Chapel Hill, Principal, Parent, National Jewish Health, Biology, Food, Allergy, Vaccine, MD, Northwestern

NEW YORK, Jan. 26, 2023 /PRNewswire-PRWeb/ -- Mount Sinai researchers have been awarded $12 million over five years by the National Institutes of Health to create a center to elucidate novel causes of, and contributing factors to, food allergies and atopic dermatitis.

Key Points: 
  • Mount Sinai researchers have been awarded $12 million over five years by the National Institutes of Health to create a center to elucidate novel causes of, and contributing factors to, food allergies and atopic dermatitis.
  • The Systems Biology of Early Atopy (SunBEAm) Analysis and Bioinformatics Center intends to develop a better understanding of allergy development.
  • NEW YORK, Jan. 26, 2023 /PRNewswire-PRWeb/ -- Mount Sinai researchers have been awarded $12 million over five years by the National Institutes of Health to create a center to elucidate novel causes of, and contributing factors to, food allergies and atopic dermatitis.
  • The Systems Biology of Early Atopy (SunBEAm) Analysis and Bioinformatics Center intends to develop a better understanding of allergy development.

New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update

Retrieved on: 
Tuesday, January 17, 2023
FCCP, Tripler Army Medical Center, EST, Cystic fibrosis, MHS, Public health, Amyotrophic lateral sclerosis, Madigan Army Medical Center, Epidemiology, Johns Hopkins Bloomberg School of Public Health, Degenerative disease, Pediatrics, Patient, KOL, CF, Johns Hopkins School of Medicine, Medicine, Doctor of Philosophy, ALS, National Jewish Health, Pharmaceutical industry, MD, Mycobacterium

Los Gatos, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced its participation in Key Opinion Leader (KOL) event focusing on the anti-infective treatment landscape in cystic fibrosis (CF) and the Company’s Phase 2a trial of AR-501 in CF patients. AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in CF patients. The KOL event will take place on January 24 at 11 a.m. EST.

Key Points: 
  • AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in CF patients.
  • The KOL event will take place on January 24 at 11 a.m. EST.
  • The virtual event will feature key opinion leaders Jane E. Gross, MD, PhD, and Noah Lechtzin, MD, MHS, FCCP.
  • Carl Byrnes, Managing Director and Senior Research Analyst at Northland Capital Markets will host and moderate the virtual KOL.

Vicore announces first patient enrolled in COMPANION; a digital therapeutic pivotal study for patients with pulmonary fibrosis

Retrieved on: 
Monday, December 5, 2022
Therapy, PF, MD, Infection, Degenerative disease, National Jewish Health, Patient, Cognitive behavioral therapy, Digital, Fatigue, Disease, FDA, Digital therapeutics, Breathe Me, Pulmonary fibrosis, Anxiety, Risk, Pharmaceutical industry, Hospital, Vicor Corporation

Patients with pulmonary fibrosis (PF) are given a poor prognosis, during which dyspnea, fatigue and cough gradually worsen.

Key Points: 
  • Patients with pulmonary fibrosis (PF) are given a poor prognosis, during which dyspnea, fatigue and cough gradually worsen.
  • In a preceding study, it was shown that 63% of PF patients report treatable levels of anxiety1.
  • Vicore's digital Cognitive Behavioral Therapy has the advantage of being accessible 24/7 and can be personalized to meet the patient's individual needs and schedule.
  • Patients enrolled in the investigation will be randomized to Almee or a treatment-as-usual control group, for nine weeks.

4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022

Retrieved on: 
Wednesday, October 26, 2022
Clinical trial, Bronchiectasis, Epithelium, Mucus, Ophthalmology, Safety, Nasdaq, Fabry disease, Choroideremia, Disease, Investor, Valencia CF Foundation, Conference, Patient, MSCS, Inflammation, Webcast, CFTR, US, Cardiology, Cystic fibrosis, National Jewish Health, Fabry, Tissue, GLOBE, Pediatrics, Mutation, Therapy, Human, Urinary tract infection, VG, Population, Science, Adult, Mortality, AMD, Respiratory disease, Pharmaceutical industry, 3D printing, Vaccine, MD, Medicine

4D Molecular Therapeutics will host a conference call and live webcast on November 3rd, 2022 at 4:30 pm E.T to further discuss the interim clinical data presented at NACFC.

Key Points: 
  • 4D Molecular Therapeutics will host a conference call and live webcast on November 3rd, 2022 at 4:30 pm E.T to further discuss the interim clinical data presented at NACFC.
  • Registration and dial-in for the conference call may be accessed through 4D Molecular Therapeutics website under Events & Presentation in the Investors section through the following link: https://ir.4dmoleculartherapeutics.com/events .
  • The presentation from NACFC will also be available on the 4D Molecular Therapeutics website under Scientific Presentations: https://4dmoleculartherapeutics.com/technology/scientific-presentations .
  • 4D Molecular Therapeutics, 4DMT, Therapeutic Vector Evolution, and the 4DMT logo are trademarks of 4DMT.

Anokion Announces Leadership Team Expansion to Support Advancement of Clinical-Stage Autoimmune Pipeline

Retrieved on: 
Thursday, October 27, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, National, Villanova University, Marketing, University, Research, Alexion, Multiple sclerosis, Johnson & Johnson, Shire, Nephrology, CRA International, Spark Therapeutics, Biogen, Therapy, Patient, Immune tolerance, Biology, Viral disease, Autoimmune disease, Regiment University of Witwatersrand, Genzyme, Acquisition, Dimension, Shire (pharmaceutical company), Sclerosis, Microbiology, Industry, Degenerative disease, Institute, Psychology, Abbott, George Mason University, National Jewish Health, Dartmouth College, Health, Haemophilia, Pharmacy, Denison University, Pfizer, Foundation for the National Institutes of Health, Head, Doctor of Philosophy, Liver, Pharmaceutical industry, Management, Daimler Freeline, EU

Anokion SA , a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced appointments to the companys leadership team to support the continued advancement of its pipeline, including its clinical-stage programs, KAN-101 and ANK-700.

Key Points: 
  • Anokion SA , a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced appointments to the companys leadership team to support the continued advancement of its pipeline, including its clinical-stage programs, KAN-101 and ANK-700.
  • Dr. Long brings extensive industry and clinical experience to Anokion, with a proven track record developing therapies, which include five successful regulatory approvals over her career.
  • She has held roles in clinical & translational development at Anokion since 2019, most recently as vice president, clinical & translational development.
  • The company is focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis and type 1 diabetes.